This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Dynavax Technologies Beheer
Beheer criteriumcontroles 2/4
De CEO Dynavax Technologies is Ryan Spencer, benoemd in Dec2019, heeft een ambtstermijn van 6.17 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 8.21M, bestaande uit 10.2% salaris en 89.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.33% van de aandelen van het bedrijf, ter waarde $ 5.88M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5 jaar en 4.3 jaar.
Belangrijke informatie
Ryan Spencer
Algemeen directeur
US$8.2m
Totale compensatie
| Percentage CEO-salaris | 10.17% |
| Dienstverband CEO | 6.2yrs |
| Eigendom CEO | 0.3% |
| Management gemiddelde ambtstermijn | 5yrs |
| Gemiddelde ambtstermijn bestuur | 4.3yrs |
Recente managementupdates
Recent updates
Analyse-update • Feb 05
DVAX: Cash Acquisition By Sanofi Will Likely Unlock Further Upside
Analysts kept their fair value estimate for Dynavax Technologies steady at US$25.00. They refined inputs such as a slightly higher discount rate, modestly adjusted revenue growth and profit margin assumptions, and a small change in the future P/E they use in their models to better reflect their updated view of the company.Analyse-update • Jan 22
DVAX: Planned Takeover Will Likely Unlock Upside From Cash Deal
Analysts have maintained their fair value estimate for Dynavax Technologies at US$25.00, with only minor adjustments to assumptions such as discount rate, revenue growth, profit margin, and future P/E to reflect updated views on the company’s risk profile and earnings potential. What's in the News Sanofi agreed to acquire Dynavax Technologies for US$1.9b in cash, valuing shares at US$15.50 each.Analyse-update • Jan 07
DVAX: Planned Sanofi Acquisition Will Likely Unlock Upside From Conservative Outlook
Analysts have revised their price target on Dynavax Technologies from $32.00 to $25.00, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E that indicate a more conservative fair value outlook. What's in the News Sanofi agreed to acquire Dynavax Technologies for a total consideration of US$1.9b, with Dynavax shareholders to receive US$15.50 in cash per share upon completion of the transaction.Analyse-artikel • Jan 06
Dynavax Technologies Corporation (NASDAQ:DVAX) Surges 42% Yet Its Low P/S Is No Reason For Excitement
Dynavax Technologies Corporation ( NASDAQ:DVAX ) shares have continued their recent momentum with a 42% gain in the...
Analyse-update • Dec 18
DVAX: Buybacks Will Support Future Upside As Pipeline Progress Strengthens Outlook
Analysts have nudged their price target on Dynavax Technologies higher to approximately $19.25 per share. This reflects slightly adjusted assumptions for discount rates, long term revenue growth, profit margins, and forward valuation multiples, which leave their overall fair value estimate broadly unchanged.Analyse-update • Dec 04
DVAX: Share Buybacks Will Drive Future Upside Despite Lowered Market Multiple
Analysts have trimmed their price target on Dynavax Technologies from 21.80 dollars to 19.25 dollars, reflecting slightly higher discount rate assumptions and a more conservative view on future valuation multiples, despite largely unchanged long term growth and margin expectations. What's in the News Board of Directors authorized a new share repurchase plan in October 2025, enabling the company to buy back common stock.Analyse-update • Nov 20
DVAX: Share Repurchase And Positive Trial Data Will Drive Further Upside
Analysts have revised their price target for Dynavax Technologies downward from $22.80 to $21.80. They cite slight adjustments to key financial assumptions, including discount rate, revenue growth, and profit margin forecasts.Analyse-artikel • Nov 08
Dynavax Technologies Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
It's been a good week for Dynavax Technologies Corporation ( NASDAQ:DVAX ) shareholders, because the company has just...Seeking Alpha • Oct 29
Dynavax Technologies Trading At Fair Value
Summary Dynavax's HEPLISAV‑B is its sole revenue generator. HEPLISAV‑B's revenue has grown steadily in a crowded market of hepatitis B vaccines. The market for these vaccines is expected to peak at ~$900 million in 2030 before tailing off afterwards. DVAX expects to grow its percentage share of the hepatitis B market to 60% by 2030. Read the full article on Seeking AlphaAnalyse-artikel • May 08
Dynavax Technologies Corporation Reported A Surprise Loss, And Analysts Have Updated Their Forecasts
There's been a notable change in appetite for Dynavax Technologies Corporation ( NASDAQ:DVAX ) shares in the week since...Analyse-artikel • Mar 04
We Think Dynavax Technologies' (NASDAQ:DVAX) Profit Is Only A Baseline For What They Can Achieve
The subdued stock price reaction suggests that Dynavax Technologies Corporation's ( NASDAQ:DVAX ) strong earnings...Seeking Alpha • Mar 03
Dynavax Technologies: A Post-Earnings Assessment With Growing Market Share
Summary Dynavax Technologies posted solid Q4 results and FY 2025 guidance late in February, with Heplisav-B driving revenue growth and profitability. Heplisav-B's market share continues to grow due to its superior efficacy and compliance compared to previous hepatitis B vaccines. Heplisav-B should eventually garner 60% of a market that is predicted to grow to $900 million in the U.S. by 2030. Dynavax Technologies also has large net cash holdings and a promising Shingles vaccine in development. An updated analysis around Dynavax Technologies follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Feb 05
Dynavax Technologies: Time To Refocus On Former Cash Cow CpG1018
Summary HEPLISLAV-B, which is adjuvanted with CpG1018, has key advantages over its principal competition, Engerix-B. The article reviews Dynavax's investment prospects following its Q3 2024 earnings report, preliminary 2024 financial results press release, and latest website presentation. Management's failure to work towards monetizing its CpG1018 adjuvant is unfortunate, in my opinion. Dynavax should take a leaf from its vaccine maker peer, Novavax, and work to monetize its CpG1018 adjuvant. Read the full article on Seeking AlphaAnalyse-artikel • Jan 24
Is Dynavax Technologies (NASDAQ:DVAX) Using Debt In A Risky Way?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Nov 13
Dynavax Technologies: What The Stock Buyback Means, What It Doesn't
Summary Today, we revisit Dynavax Technologies Corporation, whose shares have moved up nicely after the company announced a significant buyback authorization. In addition, DVAX's flagship product, Heplisav-B, continues to increase market share consistently in a growing market. The company has also moved towards profitability, and analyst firms have price targets significantly above the current trading level of the stock, even after its recent rally. An updated analysis around Dynavax Technologies follows in the paragraphs below. Read the full article on Seeking AlphaAnalyse-artikel • Nov 12
Dynavax Technologies Corporation (NASDAQ:DVAX) Surges 31% Yet Its Low P/S Is No Reason For Excitement
Dynavax Technologies Corporation ( NASDAQ:DVAX ) shareholders would be excited to see that the share price has had a...Analyse-artikel • Oct 12
Is Dynavax Technologies (NASDAQ:DVAX) Using Debt In A Risky Way?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Nieuwe analyse • Sep 14
HEPLISAV-B And New Vaccine Trials Set To Skyrocket Revenue And Market Share
Strong HEPLISAV-B sales and market optimism indicate potential for revenue growth and market share expansion in the adult hepatitis B vaccine sector.Seeking Alpha • Sep 05
Dynavax Technologies: Slow And Steady Wins The Race
Summary Today, we are revisiting Dynavax Technologies Corporation, one of my favorite “rinse, wash, and repeat” covered call trades recently. Dynavax Technologies' Heplisav-B vaccine continues to gain market share, driving solid revenue growth and profitability despite the loss of COVID-19 adjuvant sales. Despite range bound stock performance, Dynavax's profitability and decent liquidity in the options against the equity, make it an attractive investment, with minimal downside risk and potential for solid upside. An updated analysis following second quarter results in August follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Aug 23
Dynavax Technologies: A Two Trick Pony Operating With A Single Trick
Summary Dynavax has experienced fluctuations in stock performance since the author's initial coverage. HEPLISAV-B is Dynavax's primary revenue source for the foreseeable future, with CpG-1018 currently sidelined. Supported by ample liquidity, Dynavax is evaluating business development on a disciplined basis. Read the full article on Seeking AlphaAnalyse-artikel • Aug 14
Some May Be Optimistic About Dynavax Technologies' (NASDAQ:DVAX) Earnings
Dynavax Technologies Corporation's ( NASDAQ:DVAX ) stock was strong despite it releasing a soft earnings report last...Analyse-artikel • Jul 12
Is Dynavax Technologies (NASDAQ:DVAX) Weighed On By Its Debt Load?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Analyse-artikel • May 22
Lacklustre Performance Is Driving Dynavax Technologies Corporation's (NASDAQ:DVAX) Low P/S
With a price-to-sales (or "P/S") ratio of 6.4x Dynavax Technologies Corporation ( NASDAQ:DVAX ) may be sending bullish...Seeking Alpha • May 10
Dynavax: HEPLISAV-B Growth Up, Pipeline Uncertain
Summary HEPLISAV-B Q1 revenue was $48 million, showing 10% YoY growth. Dynavax's shingles and Tdap vaccines advanced in clinical stages, with data anticipated in the coming quarters. Dynavax's balance sheet remains robust with a significant cash runway. Dynavax remains a "hold," given the challenging prospects beyond the hepatitis B market. Read the full article on Seeking AlphaSeeking Alpha • Mar 23
Dynavax: Holding Firm Despite Its Missing Cash Cow
Summary Pandemic era CpG 1018 revenues are gone and unlikely to rekindle. HEPLISAV-B revenues create a reliable growing stream of income. Dynavax is fairly valued. Read the full article on Seeking AlphaAnalyse-artikel • Mar 06
Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analyse-artikel • Jan 31
Dynavax Technologies Corporation's (NASDAQ:DVAX) Business And Shares Still Trailing The Industry
Dynavax Technologies Corporation's ( NASDAQ:DVAX ) price-to-sales (or "P/S") ratio of 4.7x might make it look like a...Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$43m |
| Jun 30 2025 | n/a | n/a | -US$53m |
| Mar 31 2025 | n/a | n/a | -US$60m |
| Dec 31 2024 | US$8m | US$835k | US$27m |
| Sep 30 2024 | n/a | n/a | US$20m |
| Jun 30 2024 | n/a | n/a | US$17m |
| Mar 31 2024 | n/a | n/a | US$9m |
| Dec 31 2023 | US$6m | US$760k | -US$6m |
| Sep 30 2023 | n/a | n/a | US$61m |
| Jun 30 2023 | n/a | n/a | US$111m |
| Mar 31 2023 | n/a | n/a | US$236m |
| Dec 31 2022 | US$6m | US$695k | US$293m |
| Sep 30 2022 | n/a | n/a | US$320m |
| Jun 30 2022 | n/a | n/a | US$228m |
| Mar 31 2022 | n/a | n/a | US$104m |
| Dec 31 2021 | US$5m | US$600k | US$72m |
| Sep 30 2021 | n/a | n/a | -US$39m |
| Jun 30 2021 | n/a | n/a | -US$6m |
| Mar 31 2021 | n/a | n/a | -US$62m |
| Dec 31 2020 | US$2m | US$515k | -US$75m |
| Sep 30 2020 | n/a | n/a | -US$97m |
| Jun 30 2020 | n/a | n/a | -US$138m |
| Mar 31 2020 | n/a | n/a | -US$129m |
| Dec 31 2019 | US$3m | US$391k | -US$156m |
Compensatie versus markt: De totale vergoeding ($USD 8.21M ) Ryan } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.48M ).
Compensatie versus inkomsten: De vergoeding van Ryan is gestegen terwijl het bedrijf verliesgevend is.
CEO
Ryan Spencer (46 yo)
6.2yrs
Tenure
US$8,210,775
Compensatie
Mr. Ryan Spencer served as Independent Director at Cidara Therapeutics, Inc. from April 24, 2024 to January 7, 2026. He serves as the Chief Executive Officer and Director of Dynavax Technologies Corporatio...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 6.2yrs | US$8.21m | 0.33% $ 5.9m | |
| Senior VP & CFO | 4.9yrs | US$2.63m | 0.053% $ 933.2k | |
| Senior VP & COO | 12.9yrs | US$3.73m | 0.056% $ 981.8k | |
| Senior VP & General Counsel | 4.7yrs | US$2.85m | geen gegevens | |
| Chief Medical Officer and Senior VP of Clinical Development | 12.6yrs | US$2.28m | 0.068% $ 1.2m | |
| VP & Chief Accounting Officer | less than a year | geen gegevens | geen gegevens | |
| Senior VP & Chief Human Resources Officer | 7.1yrs | geen gegevens | geen gegevens | |
| VP of Investor Relations & Corporate Communications | 3.1yrs | geen gegevens | geen gegevens | |
| Senior VP & Chief Commercial Officer | no data | geen gegevens | geen gegevens | |
| Senior Vice President of Research | 5yrs | geen gegevens | geen gegevens | |
| VP, Site Head & MD for Dynavax GmbH | 5.1yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Commercial | less than a year | geen gegevens | geen gegevens |
5.0yrs
Gemiddelde duur
60yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van DVAX is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 6.2yrs | US$8.21m | 0.33% $ 5.9m | |
| Independent Director | 15.6yrs | US$297.64k | 0.0013% $ 23.3k | |
| Independent Director | 16.3yrs | US$285.64k | 0.018% $ 323.0k | |
| Member of Scientific Advisory Board | 3.1yrs | US$1.83m | geen gegevens | |
| Director | 1yr | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 3.1yrs | geen gegevens | geen gegevens | |
| Director | 1yr | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 3.1yrs | geen gegevens | geen gegevens | |
| Independent Director | 5.6yrs | US$285.64k | geen gegevens | |
| Independent Chairman of the Board | 4.3yrs | US$330.64k | 0.026% $ 453.4k | |
| Independent Director | 4.2yrs | US$290.64k | geen gegevens | |
| Chairman of the Scientific Advisory Board & Independent Director | 5.4yrs | US$302.39k | 0.017% $ 295.7k |
4.3yrs
Gemiddelde duur
72yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van DVAX wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/02/10 05:24 |
| Aandelenkoers aan het einde van de dag | 2026/02/09 00:00 |
| Inkomsten | 2025/09/30 |
| Jaarlijkse inkomsten | 2024/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Dynavax Technologies Corporation wordt gevolgd door 10 analisten. 3 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Elemer Piros | Cantor Fitzgerald & Co. |
| Douglas Buchanan | Citizens JMP Securities, LLC |
| Jason Butler | Citizens JMP Securities, LLC |